Relapsed Refractory Multiple Myeloma (RRMM)Symptoms, Doctors, Treatments, Advances & More
Learn About Relapsed Refractory Multiple Myeloma (RRMM)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
Paul Richardson is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Richardson is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Hepatic Venoocclusive Disease with Immunodeficiency, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Graft.
Dana-Farber Cancer Institute, Lipper Multiple Myeloma Center
Jacob Laubach is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Laubach is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.
Emory Winship Cancer Institute
Sagar Lonial is a Hematologist Oncology provider in Atlanta, Georgia. Dr. Lonial has been practicing medicine for over 33 years and is rated as an Elite provider by MediFind in the treatment of Relapsed Refractory Multiple Myeloma (RRMM). His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Aplastic Anemia, and Bone Marrow Transplant.
Summary: This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called study drug or study drugs when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if R...
Summary: This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active disease on the D30+ PET or other imaging scan after CAR-T infusion. Patients who are planned for salvage chemotherapy les...